NASDAQ: ANTX

AN2 Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ANTX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

AN2 Therapeutics, Inc. (NASDAQ: ANTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 19:45 UTC.

What AN2 Therapeutics, Inc. does

AN2 Therapeutics is a clinical stage biopharmaceutical company developing small-molecule drugs derived from its boron chemistry platform. The company's pipeline targets hematologic diseases, infectious diseases, and oncology, with ongoing clinical studies for epetraborole in polycythemia vera and Mycobacterium abscessus lung disease, and a first-in-human trial underway for AN2-502998 in Chagas disease. The company is also pursuing preclinical oncology programs focused on PI3K and ENPP1 inhibitors. AN2 aims to address critical unmet medical needs across these therapeutic areas.

Summarized from AN2 Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for ANTX are available in Oxford Ledge.
Open ANTX in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-13

2026-10-13DirectorAward2,465—
2026-10-13DirectorAward389—
2026-10-13DirectorAward2,283—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Vivo Capital, LLC3,153,640$15.26M0.0%
Commodore Capital LP2,933,680$14.20M+25.7%
MILLENNIUM MANAGEMENT LLC2,318,692$11.22M+4.3%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-01-29Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-09-08Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver
Seeking Alpha Feed2026-09-22
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Yahoo2026-08-31
Fewer than five qualifying stories — full tape in the platform →

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ANTX and 5,000+ tickers.

Create a free account — keep ANTX

For your agent

GET /api/data?ticker=ANTX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt